277 related articles for article (PubMed ID: 31844419)
1. MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
Sun JR; Zhang X; Zhang Y
Cell Mol Biol Lett; 2019; 24():68. PubMed ID: 31844419
[TBL] [Abstract][Full Text] [Related]
2. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
Wang QM; Lian GY; Song Y; Huang YF; Gong Y
Life Sci; 2019 Aug; 231():116335. PubMed ID: 30898647
[TBL] [Abstract][Full Text] [Related]
3. CircPCBP2 promotes the stemness and chemoresistance of DLBCL via targeting miR-33a/b to disinhibit PD-L1.
Dong L; Huang J; Gao X; Du J; Wang Y; Zhao L
Cancer Sci; 2022 Aug; 113(8):2888-2903. PubMed ID: 35579082
[TBL] [Abstract][Full Text] [Related]
4. Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1.
He B; Yan F; Wu C
Biomed Pharmacother; 2018 Feb; 98():95-101. PubMed ID: 29247952
[TBL] [Abstract][Full Text] [Related]
5. MiR-665 suppresses the progression of diffuse large B cell lymphoma (DLBCL) through targeting LIM and SH3 protein 1 (LASP1).
Wang Y; Guo D; Li B; Wang Y; Wang B; Wang Z; Wang M; Teng Q
Leuk Res; 2022 Jan; 112():106769. PubMed ID: 34875555
[TBL] [Abstract][Full Text] [Related]
6. LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis.
Yuan J; Yang J; Wang R; Hao H; Li J
Immunopharmacol Immunotoxicol; 2022 Jun; 44(3):429-436. PubMed ID: 35352617
[TBL] [Abstract][Full Text] [Related]
7. LncRNA SNHG14/miR-5590-3p/ZEB1 positive feedback loop promoted diffuse large B cell lymphoma progression and immune evasion through regulating PD-1/PD-L1 checkpoint.
Zhao L; Liu Y; Zhang J; Liu Y; Qi Q
Cell Death Dis; 2019 Sep; 10(10):731. PubMed ID: 31570691
[TBL] [Abstract][Full Text] [Related]
8. [Effect of
Yuan J; Han H; Dong W; Wang RC; Hao HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):96-103. PubMed ID: 36765483
[TBL] [Abstract][Full Text] [Related]
9. Geniposide inhibits proliferation and induces apoptosis of diffuse large B-cell lymphoma cells by inactivating the HCP5/miR-27b-3p/MET axis.
Hu L; Zhao J; Liu Y; Liu X; Lu Q; Zeng Z; Zhu L; Tong X; Xu Q
Int J Med Sci; 2020; 17(17):2735-2743. PubMed ID: 33162801
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of miR-222-3p Promotes the Proliferation and Inhibits the Apoptosis of Diffuse Large B-Cell Lymphoma Cells via Suppressing PPP2R2A.
Sun S; Wang H; Ji M
Technol Cancer Res Treat; 2019; 18():1533033819892256. PubMed ID: 31829105
[TBL] [Abstract][Full Text] [Related]
11. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
12. Curcumin Inhibits the Proliferation, Migration, Invasion, and Apoptosis of Diffuse Large B-Cell Lymphoma Cell Line by Regulating MiR-21/VHL Axis.
Chen L; Zhan CZ; Wang T; You H; Yao R
Yonsei Med J; 2020 Jan; 61(1):20-29. PubMed ID: 31887796
[TBL] [Abstract][Full Text] [Related]
13. LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a.
Zhang J; Chou X; Zhuang M; Zhu C; Hu Y; Cheng D; Liu Z
J Cell Biochem; 2020 Oct; 121(10):4188-4195. PubMed ID: 31898338
[TBL] [Abstract][Full Text] [Related]
14. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer.
Yan XL; Luo QY; Zhou SN; Pan WT; Zhang L; Yang DJ; Qiu MZ
Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101574. PubMed ID: 33272890
[TBL] [Abstract][Full Text] [Related]
17. EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Cristino AS; Nourse J; West RA; Sabdia MB; Law SC; Gunawardana J; Vari F; Mujaj S; Thillaiyampalam G; Snell C; Gough M; Keane C; Gandhi MK
Blood; 2019 Dec; 134(25):2261-2270. PubMed ID: 31856276
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
[TBL] [Abstract][Full Text] [Related]
19. YY1-induced long non-coding RNA PSMA3 antisense RNA 1 functions as a competing endogenous RNA for microRNA 214-5p to expedite the viability and restrict the apoptosis of bladder cancer cells via regulating programmed cell death-ligand 1.
Zhang M; Xu Y; Yin S; Qiu F
Bioengineered; 2021 Dec; 12(2):9150-9161. PubMed ID: 34720049
[TBL] [Abstract][Full Text] [Related]
20. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
